Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : DAVID SIRK's VALUE MOMENTUM PLAYS -- Ignore unavailable to you. Want to Upgrade?

To: Mr Metals who wrote (4110)	7/9/1999 8:50:00 PM
From: Cheesehead	Read Replies (1) \| Respond to of 4828

Ya, your right Metals. In fact, I own a small chunk of CLVE> But I ain't lost my ass like someone who posts on this thread. Nice news for REPR after the close. Nice call by Joe Copia! Friday July 9, 4:49 pm Eastern Time Company Press Release SOURCE: Repro-Med Systems, Inc. Repro-Med and McKinley Sign Definitive Agreement for Marketing of Freedom60(R) Infusion System Worldwide CHESTER, N.Y., July 9 /PRNewswire/ -- Repro-Med Systems, Inc., a manufacturer of medical devices for the hospital and home-care today announced that it has entered into a Definitive Agreement with McKinley Medical, LLLP, an international supplier of IV infusion systems, to market Repro-Med's Freedom60 Infusion System in the U.S. and international IV therapy markets. Financial terms of the agreement were not released. This definitive agreement gives McKinley exclusive worldwide rights to distribute Repro-Med's current portable, reusable infusion system called the Freedom60 as well as certain rights to Repro-Med's next generation intravenous infusion therapy systems including an electronic version under development to be released in the next quarter for the hospital and home care markets. McKinley plans to aggressively launch the Freedom60 through its network of distribution partners worldwide. In order to maintain exclusivity, McKinley must maintain sales performance levels for the duration of the agreement. ''The addition of the Freedom60 confirms our commitment to be the leading provider of infusion systems designed to meet the varying demands of our domestic and global customers,'' said Randy Hoffman, Pharm.D., Vice President Sales and Marketing for McKinley Medical. ''No other company can rival our portfolio of cost-effective, simple-to-use, high-performance electronic and disposable delivery devices,'' Hoffman continued. The Freedom60 is a non-electronic, reusable syringe infuser designed for precision-delivery of single medication doses. Featuring a proprietary pumping mechanism, this system applies continuous pressure to deliver antibiotics, chemotherapeutic agents and other medications requiring administration at controlled infusion rates. The Freedom60 is designed to infuse up to 60 cc of medication from a standard, disposable syringe over 30 minutes to 24 hours. ''We've always believed that we had the ideal delivery system and destined to become the 'gold standard' for effective low cost infusion therapy,'' said Marion Howarth, Vice President Sales for Repro-Med Systems, Inc. ''Repro-Med can now offer its state-of-the-art infusion technologies through McKinley's focused, knowledgeable worldwide distribution network,'' Howarth said. Repro-Med Systems, Inc. of Chester, New York, designs, develops and manufactures specialty products for emergency-care, hospital, home care markets and for direct patient use. These include the Res-Q-Vac® Emergency Suction System, the Plus® resuscitator, RESTORE® for male infertility, the Repro-Med THD for male infertility, and gynecological products under the trademark name of Gyneco® and Masterson®. SOURCE: Repro-Med Systems, Inc. Cheese